Paying users zone. Data is covered by .
Get to Regeneron Pharmaceuticals Inc. for $13.99, or
get to whole website for at least 3 months from $49.99.
Basic information about Regeneron Pharmaceuticals Inc.
The income statement (statement of earnings) reports on the performance of Regeneron Pharmaceuticals Inc., the result of its operating activities.
Comprehensive income is the change in equity (net assets) of Regeneron Pharmaceuticals Inc. during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
The assets reports major classes and amounts of resources owned or controlled by Regeneron Pharmaceuticals Inc..
The liabilities and stockholders' equity reports major classes and amounts of external claims on assets and owners' capital contributions, and other internally generated sources of capital.
The cash flow statement provides information about Regeneron Pharmaceuticals Inc.'s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on Regeneron Pharmaceuticals Inc.'s statement of financial position.
Common-Size Financial Statements
Income statement components (revenues and expenses) shown as percentage of total sales.
Assets components shown as percentage of total assets.
Liabilities and stockholders' equity components shown as percentage of total liabilities and stockholders' equity.
Evaluates revenues and output generated by the Regeneron Pharmaceuticals Inc.'s assets. Operating performance ratios describe the relationship between the Regeneron Pharmaceuticals Inc.'s level of operations and the assets needed to sustain operating activities.
Measures the adequacy of Regeneron Pharmaceuticals Inc.'s cash resources to meet its near-term cash obligations.
Measures the income of Regeneron Pharmaceuticals Inc. relative to its revenues and invested capital.
An approach to decomposing Regeneron Pharmaceuticals Inc.'s return on equity as the product of other financial ratios.
Relative valuation technique determine the value of Regeneron Pharmaceuticals Inc. by comparing it to similar entities (like industry or sector) on the basis of several relative ratios that compare its stock price to relevant variables that affect the stock's value, such as earnings, book value, and sales.
To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital.
Free cash flow to the firm is the cash flow available to the Regeneron Pharmaceuticals Inc.'s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made.
Free cash flow to equity is the cash flow available to Regeneron Pharmaceuticals Inc.'s equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made.
Discounted Cash Flow (DCF) Valuation
CAPM is a theory concentrated with deriving the expected rates of return on risky assets based on the assets' systematic risk levels. Systematic risk is the variability of returns that is due to macroeconomic factors that affect all risky assets. It cannot be eliminated by diversification.
The Dividend Discount Model (DDM) is a technique for estimating the value of a share of Regeneron Pharmaceuticals Inc.'s common stock issue as the present value of all future dividends.
The FCFF valuation approach estimates the value of the firm as the present value of future FCFF discounted at the weighted average cost of capital (WACC).
Economic Value Added (EVA)
Internal management performance measure that compares net operating profit after taxes to total cost of capital. Indicates how profitable Regeneron Pharmaceuticals Inc. projects are as a sign of management performance.
Main items of Regeneron Pharmaceuticals Inc.'s financial statements.
Regeneron Pharmaceuticals Inc.'s activity ratio calculated as total revenue divided by total assets.
Regeneron Pharmaceuticals Inc.'s liquidity ratio calculated as current assets divided by current liabilities.
Regeneron Pharmaceuticals Inc.'s solvency ratio calculated as total debt divided by total shareholders' equity.
Regeneron Pharmaceuticals Inc.'s profitability ratio calculated as operating income divided by revenue.
Regeneron Pharmaceuticals Inc.'s indicator of profitability, calculated as net income divided by revenue.
Regeneron Pharmaceuticals Inc.'s profitability ratio calculated as net income divided by shareholders' equity.
Regeneron Pharmaceuticals Inc.'s profitability ratio calculated as net income divided by total assets.
The P/E ratio tells analyst how much an investor in Regeneron Pharmaceuticals Inc.'s common stock pays per dollar of current earnings.
An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.
The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return.
- Income Tax Accounting Policy
- Income Tax Expense (Benefit)
- Effective Income Tax Rate (EITR)
- Components of Deferred Tax Assets and Liabilities
- Deferred Tax Assets and Liabilities, Classification
- Analyst Adjustments: Removal of Deferred Taxes
- Adjusted Ratios: Removal of Deferred Taxes (Summary)
- Adjusted Current Ratio
- Adjusted Net Profit Margin
- Adjusted Total Asset Turnover
- Adjusted Financial Leverage
- Adjusted Return on Equity (ROE)
- Adjusted Return on Assets (ROA)
- Present Value of Future Operating Lease Payments
- Analyst Adjustments for Operating Leases
- Adjusted Ratios for Operating Leases (Summary)
- Adjusted Total Asset Turnover
- Adjusted Debt to Equity
- Adjusted Return on Assets (ROA)
- Adjusted Interest Coverage
- Estimation of Depreciation Expense, Operating Leased Assets
- Estimation of Interest Expense, Operating Lease Obligations
- Present Value of Operating Lease Payments, at Beginning of Year
Differences in accounting methods affect comparisons between companies, and analysts make adjustments to reported financial statements in the interest of comparability.
Differences in accounting methods affect financial ratio comparisons between companies, and analysts make adjustments to reported financials in the interest of comparability.
Financial Reporting Quality
Financial reporting quality relates to the accuracy with which Regeneron Pharmaceuticals Inc.'s reported financial statements reflect its operating performance and to their usefulness for forecasting future cash flows.
Aggregate accruals deriving measures of the accrual component of Regeneron Pharmaceuticals Inc.'s earnings.